B
Bruce M. Travis
Researcher at Bristol-Myers Squibb
Publications - 23
Citations - 1384
Bruce M. Travis is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Virus & Antigen. The author has an hindex of 16, co-authored 23 publications receiving 1358 citations. Previous affiliations of Bruce M. Travis include University of Washington.
Papers
More filters
Journal ArticleDOI
Plasma viremia in macaques infected with simian immunodeficiency virus : plasma viral load early in infection predicts survival
Andrew Watson,Jane E. Ranchalis,Bruce M. Travis,Janela McClure,William F. Sutton,Philip R. Johnson,Shiu Lok Hu,Nancy L. Haigwood +7 more
TL;DR: Findings are consistent with the available clinical data concerning viral load correlates early in HIV infection, and they provide further support for the view that disease outcome in lentiviral infection may be largely determined by events that occur shortly after infection.
Journal ArticleDOI
Removal of a Single N-Linked Glycan in Human Immunodeficiency Virus Type 1 gp120 Results in an Enhanced Ability To Induce Neutralizing Antibody Responses
Yun Li,Bradley Cleveland,Igor Klots,Bruce M. Travis,Barbra A. Richardson,David E. Anderson,David C. Montefiori,Patricia Polacino,Shiu Lok Hu +8 more
TL;DR: The immunogenicity of mutant Env and the potential advantages for glycan modification in vaccine design are indicated, although the role of specific glycans requires further examination.
Journal ArticleDOI
Enhancing the Proteolytic Maturation of Human Immunodeficiency Virus Type 1 Envelope Glycoproteins
James M. Binley,Rogier W. Sanders,Rogier W. Sanders,Aditi Master,Charmagne Cayanan,Cheryl Wiley,Linnea Schiffner,Bruce M. Travis,Shawn E. Kuhmann,Dennis R. Burton,Shiu Lok Hu,William C. Olson,John P. Moore +12 more
TL;DR: Coexpression of Env cleavage site mutants and furin is a useful method for obtaining high-level expression of processed Env and not significantly reduced by furin coexpression.
Journal ArticleDOI
Human immunodeficiency virus-like, nonreplicating, gag-env particles assemble in a recombinant vaccinia virus expression system.
TL;DR: The assembly of human immunodeficiency virus (HIV)-like particles in African green monkey kidney cells coinfected with two recombinant vaccinia viruses, one carrying the HIV-1 gag and protease genes and the other the env gene provides a novel and attractive approach for vaccine development.
Journal ArticleDOI
Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile
Nancy L. Haigwood,Andrew Watson,William F. Sutton,Jan McClure,Anne D. Lewis,Jane E. Ranchalis,Bruce M. Travis,Gerald Voss,Norman L. Letvin,Shiu Lok Hu,Vanessa M. Hirsch,Philip R. Johnson +11 more
TL;DR: It is hypothesize that SIVIG reduced the spread of virus by eliminating or reducing plasma virus through immune complexes during the first four to 8 weeks of infection and then maintaining this low level of viremia until the host immune response was capable of virus control.